Sintilimab (IBI308) in Combination With Chidamide and Azacitidine in Refractory or Relapsed PTCL - Trial NCT04052659
Access comprehensive clinical trial information for NCT04052659 through Pure Global AI's free database. This Phase 2 trial is sponsored by Peking University and is currently Not yet recruiting. The study focuses on Peripheral T-cell Lymphoma. Target enrollment is 30 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Peking University
Timeline & Enrollment
Phase 2
Apr 15, 2021
Dec 30, 2025
Primary Outcome
Objective response rate (ORR) by Lugano 2014 up to 24 months
Summary
This is a single-arm, single-center Phase II clinical trial for patients with relapsed or
 refractory Peripheral T-cell lymphoma (PTCL). Immunotherapy with anti-PD-1 antibodies, such
 as sintilimab, may help the body's immune system attack the cancer, and may interfere with
 the ability of tumor cells to grow and spread. Chidamide and azacitidine may respectively
 stop the growth of tumor cells by blocking histone deacetylation and DNA methylation enzymes
 needed for cell growth. Giving chidamide and azacitidine with sintilimab these three drugs
 may work better than single drug or combination of two drugs in treating patients with
 relapsed or refractory peripheral T-cell lymphoma.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT04052659
Non-Device Trial